Citations

Clear

334 citation(s) found for "Jacobs, C".

A multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever, Nalan, Jacobs, Jeremy W. , Park, Yara A. , Lauro, Deisen, Torres, Sarina, Ward, Dawn C. , Stephens, Laura D. , Adkins, Brian D. , Yurtsever, Nalan , Stephens, Laura , Tormey, Christopher A , Adkins, Brian David , Jacobs, Jeremy W , Yurtsever, Nalan , Booth, Garrett S. , Schwartz, Joseph E. , Woo, Jennifer S. , Allen, Elizabeth S. , Tormey, Christopher A.

Mayo Clinic

Journal of Clinical Apheresis | July 9, 2024 | Volume: 39 | Issue: 4 | Pages: No page available

10.1002/jca.22138 | PMID 38979705 Get It

AbstractIntroductionApheresis practices in the United States (US) have not been comprehensively characterized to date. This study aimed to address this gap by evaluating apheresis therapy through a national survey.MethodsA multi‐institutional survey was conducted between April and July 2023. The survey, comprising 54 questions, focused on institutional demographics, procedures, equipment, staffing, training, and impacts of the Coronavirus Disease 2019 (COVID‐19) pandemic. Responses from 22 institutions, primarily academic medical centers, were analyzed.ResultsTherapeutic plasma exchange (TPE) was the most common procedure, followed by hematopoietic progenitor cell collection (HPC‐A) and red blood cell exchange (RCE). CAR‐T cell collections were widespread, with some institutions supporting over 30 protocols concurrently. Most sites used the Spectra Optia Apheresis System, were managed by a transfusion medicine service, and employed internal apheresis providers. Insufficient staffing levels, exacerbated by the COVID‐19 pandemic, were common and most often addressed using overtime.DiscussionThe survey highlighted the ubiquity of TPE, expanding cellular collections and staffing challenges. The role of apheresis in supporting cellular therapy, particularly in newly developing cell and gene therapies and clinical trials, was evident. Staffing issues during the pandemic emphasized the need for innovative recruitment strategies.ConclusionThis nationwide survey provides the most comprehensive analysis to date of apheresis practices in large US academic centers.
Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
Debban, Catherine L., Ambalavanan, Amirthagowri , Ghosh, Auyon , Buschur, Kristina L., Ma, Yanlin , George, Elizabeth , Pistenmaa, Carrie L. , Bertoni, Alain G. , Oelsner, Elizabeth C. , Moraes, Theo J. , Jacobs, David R. , Christenson, Stephanie A. , Bhatt, Surya P. , Simons, Elinor , Turvey, Stuart E. , Vameghestahbanati, Motahareh , Bourbeau, Jean , Tan, Wan C. , Gabriel, Stacey , Gupta, Namrata , Woodruff, Prescott G. , Ortega, Victor E. , Bleecker, Eugene R. , Meyers, Deborah A. , Hoffman, Eric A. , Barr, R. Graham, Duan, Qing , Smith, Benjamin M. , George, Elizabeth , Bertoni, Alain G , Oelsner, Elizabeth C , Michos, Erin D , Moraes, Theo J , Bhatt, Surya P , Turvey, Stuart E , Engert, James C , Kirby, Miranda , Tan, Wan C , Woodruff, Prescott G , Subbarao, Padmaja , Rich, Stephen S , Hoffman, Eric A , Cho, Michael H , Bossé, Yohan , Duan, Qingling , Manichaikul, Ani W , Ghosh, Auyon J , Jacobs, David R , Christenson, Stephanie A , Ambalavanan, Amirthagowri , Li, Zhonglin , Michos, Erin D. , Kaner, Robert J. , Rich, Stephen S. , Cho, Michael H. , Bossé, Yohan , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 27, 2024 | Volume: 210 | Issue: 12 | Pages: 1421-1431

10.1164/rccm.202401-0011oc | PMID 38935874 Get It

Abstract Rationale Dysanapsis refers to a mismatch between airway tree caliber and lung size arising early in life. Dysanapsis assessed by computed tomography (CT) is evident by early adulthood and associated with chronic obstructive pulmonary disease (COPD) risk later in life. Objectives By examining the genetic factors associated with CT-assessed dysanapsis, we aimed to elucidate its molecular underpinnings and physiological significance across the lifespan. Methods We performed a genome-wide association study of CT-assessed dysanapsis in 11,951 adults, including individuals from two population-based and two COPD-enriched studies. We applied colocalization analysis to integrate genome-wide association study and gene expression data from whole blood and lung. Genetic variants associated with dysanapsis were combined into a genetic risk score that was applied to examine association with lung function in children from a population-based birth cohort (n = 1,278) and adults from the UKBiobank (n = 369,157). Measurements and Main Results CT-assessed dysanapsis was associated with genetic variants from 21 independent signals in 19 gene regions, implicating HHIP (hedgehog interacting protein), DSP, and NPNT as potential molecular targets based on colocalization of their expression. A higher dysanapsis genetic risk score was associated with obstructive spirometry among 5-year-old children and among adults in the fifth, sixth, and seventh decades of life. Conclusions CT-assessed dysanapsis is associated with variation in genes previously implicated in lung development, and dysanapsis genetic risk is associated with obstructive lung function from early life through older adulthood. Dysanapsis may represent an endophenotype link between the genetic variations associated with lung function and COPD.
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapyversus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repa
Lima, Caio Max Sao Pedro Rocha , Puhalla, Shannon L. , Guthrie, Katherine A. , Blanke, Charles D. , Jacobs, Samuel A., Hong, Theodore S. , Höchster, Howard S. , Overman, Michael J. , Yothers, Greg , Sanoff, Hanna K. , Cohen, Deirdre J , Henry, N. Lynn , Ganz, Patricia A. , Kopetz, Scott , Lucas, Peter C. , Wolmark, Norman , George, Thomas J.

Mayo Clinic

Journal of Clinical Oncology | June 21, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3632-TPS3632

10.1200/jco.2024.42.16_suppl.tps3632 Get It

TPS3632 Background: Approximately 45% of dMMR/MSI-H mCRC in the immunotherapy arm progressed at 12 mos (KEYNOTE 177). We hypothesize that dMMR/MSI-H mCRC patients (pts) may be more effectively treated with the combination of PD-1/PD-L1 (PD-1) pathway blockade and mFOLFOX6/bevacizumab (bev) rather than with anti-PD-L1 therapy (atezo) alone. Preclinical work demonstrated synergistic effects between anti-PD-1/anti-VEGF as well as between oxaliplatin/anti-PD-1 in murine CRC models, and phase II data showed activity of anti-PD-1/anti-VEGF in chemotherapy refractory colon cancer. Upon AtezoTRIBE subgroup analysis of the 8 pts with dMMR mCRC treated with FOLFOXIRI+bev+atezo, median PFS was not reached, with the first pt having progression ~16 mos. Additionally, in other solid tumor malignancies, anti-PD-1 plus anti-VEGFr (i.e., HCC and RCC) as well as anti-PD-1 plus chemotherapy (i.e., gastroesophageal and lung cancers) combinations are standard first-line treatments. Methods: This two-arm prospective phase III open-label trial randomizes (1:1) mCRC dMMR/MSI-H to atezo monotherapy v mFOLFOX6/bev+atezo combination. Key inclusion criteria have been simplified on recent amendments to better mirror clinical practice for pts receiving mFOLFOX6/bev+atezo: One cycle of FOLFOX or CAPOX, with or without bev (or biosimilar) prior to enrollment allowed, dMMR tumor determined by local CLIA-certified IHC assay (MLH1/MSH2/MSH6/PMS2) or MSI-H by local CLIA-certified PCR or NGS panel; pts with total bilirubin ≤4.0 x ULN; duration of therapy for up to two years for both arms; imaging frequency on post-treatment follow-up have been reduced; as has measurable disease per RECIST. Primary endpoint is PFS. Assuming the atezo monotherapy control arm has a 48% PFS at 24 mos as assessed by site investigator, we have 80% power to detect a hazard ratio of 0.6 (equivalent to 64.4% PFS at 24 mos) with alpha 0.025 one-sided. Stratification factors include BRAFV600E status, metastatic site, and prior adjuvant CRC therapy. Secondary endpoints include overall survival, objective response rate, safety profile, disease control rate, and duration of response. Archived tumor tissue and blood samples will be collected for correlative studies. Harmonization of translational analyses is planned between GI004 (COMMIT) and A021502 (ATOMIC). Sample size has been modified with the accrual goal of 120 pts randomized between the two immunotherapy arms needed for study completion. Enrollment actively continues. Current accrual (as of 02-02-2024): 96/120. NCT02997228. Support: U10CA180868, -180822, -180888, UG1CA189867, U24CA196067; Genentech, Inc. Clinical trial information: NCT02997228 .
Riluzole for Degenerative Cervical Myelopathy
Pedro, Karlo M. , Badhiwala, Jetan H. , Ahn, Henry, Shaffrey, Christopher I. , Mummaneni, Praveen V. , Jacobs, W. Bradley , Riew, K. Daniel , Hilibrand, Alan S. , Kim, Kee D. , Fourney, Daryl R. , Santaguida, Carlo , Massicotte, Eric M. , Fehlings, Michael G. , Alvi, Mohammed Ali , Farhadi, H. Francis , Nassr, Ahmad , Arnold, Paul M. , Riew, Kiehyun Daniel , Kelly, Michael P. , Brodke, Darrel Scott , Vaccaro, Alexander R. , Wilson, Jason, Harrop, James Shields , Huang, Peng

Mayo Clinic

JAMA Network Open | June 21, 2024 | Volume: 7 | Issue: 6 | Pages: e2415643

10.1001/jamanetworkopen.2024.15643 | PMID 38904964 Get It

Importance The modified Japanese Orthopaedic Association (mJOA) scale is the most common scale used to represent outcomes of degenerative cervical myelopathy (DCM); however, it lacks consideration for neck pain scores and neglects the multidimensional aspect of recovery after surgery. Objective To use a global statistical approach that incorporates assessments of multiple outcomes to reassess the efficacy of riluzole in patients undergoing spinal surgery for DCM. Design, Setting, and Participants This was a secondary analysis of prespecified secondary end points within the Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-PROTECT) trial, a multicenter, double-blind, phase 3 randomized clinical trial conducted from January 2012 to May 2017. Adult surgical patients with DCM with moderate to severe myelopathy (mJOA scale score of 8-14) were randomized to receive either riluzole or placebo. The present study was conducted from July to December 2023. Intervention Riluzole (50 mg twice daily) or placebo for a total of 6 weeks, including 2 weeks prior to surgery and 4 weeks following surgery. Main Outcomes and Measures The primary outcome measure was a difference in clinical improvement from baseline to 1-year follow-up, assessed using a global statistical test (GST). The 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS), arm and neck pain numeric rating scale (NRS) scores, American Spinal Injury Association (ASIA) motor score, and Nurick grade were combined into a single summary statistic known as the global treatment effect (GTE). Results Overall, 290 patients (riluzole group, 141; placebo group, 149; mean [SD] age, 59 [10.1] years; 161 [56%] male) were included. Riluzole showed a significantly higher probability of global improvement compared with placebo at 1-year follow-up (GTE, 0.08; 95% CI, 0.00-0.16; P = .02). A similar favorable global response was seen at 35 days and 6 months (GTE for both, 0.07; 95% CI, −0.01 to 0.15; P = .04), although the results were not statistically significant. Riluzole-treated patients had at least a 54% likelihood of achieving better outcomes at 1 year compared with the placebo group. The ASIA motor score and neck and arm pain NRS combination at 1 year provided the best-fit parsimonious model for detecting a benefit of riluzole (GTE, 0.11; 95% CI, 0.02-0.16; P = .007). Conclusions and Relevance In this secondary analysis of the CSM-PROTECT trial using a global outcome technique, riluzole was associated with improved clinical outcomes in patients with DCM. The GST offered probability-based results capable of representing diverse outcome scales and should be considered in future studies assessing spine surgery outcomes.
Analysis of Pediatric Clinical Practice Guideline Authors by Gender, Race, and Ethnicity
Martin, Amarilis , Allan, Jessica M. , Booth, Garrett S. , Spector, Nancy D., Overholser, Barbara , Silver, Julie , Booth, Garrett , Jacobs, Jeremy W. , Armijo, Priscila Rodrígues , Spector, Nancy Dollase , Silver, Julie K.

Mayo Clinic

Journal of Women's Health | June 6, 2024 | Volume: 33 | Issue: 8 | Pages: 1052-1062

10.1089/jwh.2023.1132 | PMID 38842430 Get It

Background and Objectives: Clinical practice guidelines (CPGs) have significantly influenced medical practice worldwide. Nevertheless, the authorship of CPGs produced by several medical societies has not been representative of the field and population they address, as women and individuals from racial and ethnic minority groups have been underrepresented as authors. We hypothesized that women and individuals from minoritized racial and ethnic groups would also be underrepresented as authors of CPGs produced by the American Academy of Pediatrics (AAP). Methods: In this cross-sectional study, the gender, race, and ethnic composition of authors and subcommittee participants of AAP-produced CPGs published from January 2010 through May 2023 were analyzed and compared to the 2010 and 2021 U.S. population and 2010 and 2022 U.S. medical school pediatric faculty. Results: Women (39.7%, 127/320 of all positions, and 42.5%, 85/200 of named author positions) and women physicians (35.2%, 101/287 of all positions, and 36.4%, 64/176 of named author positions) were significantly underrepresented—while men and men physicians were significantly overrepresented—from their respective composition in the U.S. Census and pediatric faculty. Women and women physicians from all racial and ethnic groups and men and men physicians from minority racial and ethnic groups were significantly underrepresented—from their respective composition in the U.S. Census and pediatric faculty. No Black man was identified as an author. Conclusions: Medical societies that produce CPGs should be cognizant of these inequities and ensure appropriate authorship diversity.
Abstract P199: Oral Microbiome Potentially Modifies the Cardiometabolic Benefits of Nitrate Consumption: Results From the Oral Infections Glucose Intolerance and Insulin Resistance Study (ORIGINS)
Roy, Sumith , Paster, Bruce J. , Chen, Ching-Yuan, Rosenbaum, Michael , Colombo, Paolo , Desvarieux, Moı̈se, Goh, Charlene Enhui , Bohn, Bruno , Genkinger, Jeanine M. , Molinsky, Rebecca , Chen, Ching‐Yuan, Yuzefpolskaya, M. , Knight, Rob , Papapanou, Panos N , Jacobs, David R. , Demmer, Ryan T.

Mayo Clinic

Circulation | May 16, 2024 | Volume: 149 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.149.suppl_1.p199 Get It

Background: Dietary nitrate consumption is associated with cardiometabolic health in many but not all studies. The enterosalivary nitrate-nitrite-nitric oxide (NO 3 - NO 2 - NO) pathway requires the oral microbiome for NO production (a signaling molecule beneficial to cardiometabolic health) following nitrate intake. We hypothesize that the oral microbiome modifies the cardiometabolic benefits of nitrate intake. Methods: We analyzed cross-sectional data from 657 ORGINS participants. Dietary nitrate intakes and alternative healthy eating index (AHEI) scores were calculated from food frequency questionnaire responses and a US food database. Subgingival 16S rRNA microbial genes (Illumina, MiSeq) were sequenced, and PICRUSt2 estimated metagenomic content. The Microbiome Induced Nitric oxide Enrichment Score (MINES) was calculated as a microbial gene abundance ratio representing enhanced net capacity for NO generation. Cardiometabolic biomarker (systolic and diastolic blood pressure, HbA1C, glucose, insulin, and HOMA-IR) Z-scores were averaged to form a cardiometabolic Z-score (CMZ). Adjusted multivariable linear models regressed CMZ and individual Z-scores on nitrate intake tertiles. Results: Participants were mean age 31±9, 72% female, 31% White, 14% Black, and 28% Hispanic. Mean nitrate intake was 189±171 mg/day. Higher nitrate intake was significantly associated with lower CMZ, glucose, insulin, and HOMA-IR. Mean CMZ(SE) across dietary nitrate tertiles were 0.53(0.30), 0.35(0.31), and -0.11(0.30), p for trend=0.04; findings were attenuated after adjustment for AHEI (p for trend=0.12). In subgroup analysis by MINES level, higher nitrate intake was only associated with lower cardiometabolic biomarker levels among participants with a <median MINES even after AHEI adjustment (Table). Conclusion: Higher dietary nitrate intake was associated with lower cardiometabolic risk biomarker levels only among those with reduced potential for oral microbiome-dependent NO generation.
Airway Mucus Plugging and Cause-specific Mortality in COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Abdalla, M., Díaz, Alejandro A.

Mayo Clinic

C24. CLINICAL, BIOLOGIC, AND RADIOLOGIC MARKERS OF KEY OUTCOMES AND TREATMENT RESPONSE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5122-A5122

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5122 Get It

SARS-CoV-2 Viremia Associates With Thrombosis and Mortality in the ACTIV-4a Trial
Zuchelkowski, Benjamin E. , Naqvi, Asma , Qin, S., Zhang, Li , Morris, Amy, Jacobs, Jordan, Nouraie, Mehdi , Zhang, Y., Dela Cruz, Charles S , McVerry, Bryan J , Morris, A., Neal, Matthew D , Seheult, Jansen N. , Kitsios, Georgios D , Mellors, John W , Kim, P., Bain, William G

Mayo Clinic

C18. TRANSLATING SCIENCE IN RESPIRATORY INFECTIONS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5011-A5011

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5011 Get It

Socioeconomic Deprivation Is Associated With Prevalence and Persistence of Airway Mucus Plugs in Patients With COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, R. San José , Abdalla, Mazen A. , Díaz, Alejandro A.

Mayo Clinic

A54. EXPLORING ASTHMA AND COPD: DIVERSE INSIGHTS FROM GLOBAL PERSPECTIVES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2110-A2110

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2110 Get It

Airway Mucus Plugging in Upper Versus Lower Lobes and Associations With Outcomes in COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Abdalla, Mazen A. , Díaz, Alejandro A.

Mayo Clinic

A29. WHAT IS YOUR DAMAGE? IMAGING-BASED PHENOTYPES OF COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1247-A1247

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1247 Get It